Moss Adams Wealth Advisors LLC Buys 923 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moss Adams Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 212.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,357 shares of the biopharmaceutical company's stock after buying an additional 923 shares during the quarter. Moss Adams Wealth Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $967,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 14 shares during the period. Ieq Capital LLC increased its position in Regeneron Pharmaceuticals by 10.1% in the second quarter. Ieq Capital LLC now owns 5,531 shares of the biopharmaceutical company's stock worth $5,814,000 after purchasing an additional 507 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in Regeneron Pharmaceuticals by 25.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,980 shares of the biopharmaceutical company's stock worth $3,132,000 after purchasing an additional 612 shares during the period. Canada Pension Plan Investment Board lifted its position in Regeneron Pharmaceuticals by 7.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 134,762 shares of the biopharmaceutical company's stock valued at $141,639,000 after purchasing an additional 9,472 shares during the period. Finally, AE Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company's stock valued at $575,000 after purchasing an additional 89 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.7 %

NASDAQ:REGN traded down $11.65 during trading hours on Friday, reaching $681.58. 1,107,622 shares of the stock were exchanged, compared to its average volume of 678,713. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The firm has a 50 day moving average of $738.60 and a 200 day moving average of $949.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.